WCA
BIO icon

Waratah Capital Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Waratah Capital Advisors’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,271
Closed -$440K – 124
2024
Q1 		$440K Buy
+1,271
New +$418K 0.01% 141
2022
Q4 		– Sell
-5,524
Closed -$2.3M – 193
2022
Q3 		$2.3M Buy
5,524
+320
+6% +$160K 0.04% 117
2022
Q2 		$2.57M Buy
5,204
+3,429
+193% +$1.79M 0.06% 111
2022
Q1 		$1M Buy
+1,775
New +$1.07M 0.01% 154

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Waratah Capital Advisors's BIO Position: Q2 2024 in Review

Waratah Capital Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 1,271 shares — an estimated $440K sold.

Waratah Capital Advisors first reported a position in BIO in Q1 2022 and held it in 4 quarters. The position peaked at $2.57M in Q2 2022. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

  • Waratah Capital Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
  • Waratah Capital Advisors sold 1,271 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $440K.
  • Waratah Capital Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2022 and held it in 4 quarters.
  • Waratah Capital Advisors's Bio-Rad Laboratories Class A position peaked at $2.57M in Q2 2022.
  • 440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Waratah Capital Advisors's 13F filing for Q2 2024, filed 12 Aug 2024.